Login / Signup

Association of Fentanyl Test Strip Use, Perceived Overdose Risk, and Naloxone Possession among People Who Use Drugs.

Alyssa Shell TilhouJen ZaborekAmelia BaltesElizabeth Salisbury-AfsharJulia MalickiRandall Brown
Published in: Substance use & misuse (2023)
Background: As opioid overdoses continue rising, interventions are needed to expand naloxone carriage, an opioid overdose reversal agent. Use of fentanyl test strips (FTS) might promote naloxone carriage. This study examines the relationship between FTS use, perceived overdose risk, and naloxone carriage in Wisconsin, United States. Methods: In a survey of people who use drugs ( n  = 341) in southern Wisconsin, respondents were asked about FTS use, perceived overdose risk, and how often they (1) have naloxone, (2) have more than one dose of naloxone, and (3) the number of naloxone doses possessed currently. Likert responses were mapped to an integer scale. Ordinal and linear multivariable regression examined the relationship between FTS use and study outcomes while adjusting for respondent characteristics. Results: Most respondents were male (59.6%), identified heroin as their drug of choice (70.7%) and reported intravenous use (87.9%). In unadjusted models, FTS use was associated with more often having naloxone (OR: 2.10; p  = 0.005), more often having multiple naloxone doses (OR: 2.98; p  < 0.001), and possessing a greater number of naloxone doses (dose count difference: 2.85; p  = 0.001). In adjusted models, FTS use was associated with more often having multiple naloxone doses (OR: 2.29; p  = 0.005) and possessing a greater number of naloxone doses (dose count difference: 2.25, p  = 0.020). Conclusions: Individuals who use FTS more often carry multiple doses relative to individuals who do not use FTS. Given that naloxone carriage is critical for reducing opioid overdose risk, expanding FTS use may offer a strategy to reduce opioid overdose rates via improved naloxone carriage.
Keyphrases
  • chronic pain
  • pain management
  • physical activity
  • mental health
  • social support
  • depressive symptoms
  • type diabetes
  • adipose tissue
  • high dose
  • adverse drug